Keith A. Meister

Keith A. Meister sold 669,596 shares for $107,042,630.86 across 17 transactions over 4 days at ILMN.

Director Keith A. Meister executed 17 separate sales totaling 669,596 shares for $107,042,630.86 between May 28 and June 1, 2026, reducing his non-derivative holdings from 3,500,048 shares to 2,830,452 shares. The sales occurred across a blended average price of $159.86, slightly below the current price of $164.40, while ILMN trades at only -0.6% from its 52-week high of $165.37. His prior sells at ILMN have consistently underperformed: five recent sales on May 14 posted 30-day and 90-day returns of +10.3% to +13.1%, and the TIMING PATTERN reflects 0 of 5 prior sells were well-timed at the 90-day mark, indicating a pattern of selling before rallies rather than before declines. The stock's 30-day momentum of +21.1% and 90-day strength of +26.9% suggest the timing may follow the same pattern of prior underperformance, though the multi-day execution window and structured nature of these sales warrant monitoring to determine if this represents opportunistic reduction or part of a broader portfolio rebalancing.

Director Meister buys 351,273 shares across 6 trades for $13.8M (avg $39.19) as stock falls 76.2% from 52-week high

Director Keith A. Meister executed 6 separate open-market purchases totaling 351,273 shares for $13,765,344.69 over three days (May 13–15, 2026), raising his holdings from 4,433,297 to 4,784,570 shares. The purchases occurred as the stock was in sharp decline, trading at $40.75 currently, which is -76.2% from the 52-week high of $170.87, and down -39.6% over the prior 30 days and -54.8% over 90 days. Across his 5 prior trades at WGS, Meister's timing outcomes were mixed: only 2 of 5 prior buys yielded positive 90-day returns. The company is unprofitable with net income of $-63,316,000.00 against revenue of $102,254,000.00 (latest quarter), though it shows annual revenue growth of +40.0%. The scale and timing of this multi-transaction purchase in a volatile, unprofitable biotech context warrant attention to underlying company conditions and Meister's conviction in the recovery thesis.

Director Keith A. Meister sells 329,460 shares of ILMN for $47,931,974.51 across three days (May 12-14, 2026).

Director Meister sold 329,460 shares for $47,931,974.51 across three trading sessions, with transaction prices ranging from $102.82 to $148.14. His cross-ticker track record shows only 1 prior sell with a 90d well-timed rate of 0.00%, making this recent transaction his second open-market sale on record—a notable departure from his 19 prior buys at this and other companies. The timing is neutral to slightly unfavorable: stock is currently at $143.24 (7.9% below the 52-week high of $155.53), and his sales occurred near current price levels, capturing some of the recent momentum (30-day change: +9.9%) but not significantly ahead of or behind the market. Post-transaction, Meister retains 3,500,048 shares, indicating this was not a full exit. The irregular price progression and multi-day execution suggest a structured liquidation rather than a concentrated market signal.

Director Meister acquires over 1.2M shares across 13 transactions; stock down 76% from 52-week high amid unprofitable operations and poor timing history at this ticker.

Keith Meister, a director and 10% beneficial owner of GeneDx, deployed substantial capital across 13 open-market purchases in early May, acquiring over 1.2 million shares at prices ranging from the mid-$35s to low-$41s. The stock is trading well below its 52-week high and has declined significantly over recent months, creating a classic "buying the dip" scenario. However, Meister's track record at this specific company is concerning: all five of his prior purchases at GeneDx in March yielded substantial subsequent declines over both the 30-day and 90-day periods that followed, and his broader insider track record across all securities shows minimal success with open-market buys. Additionally, GeneDx remains unprofitable with operating losses in its latest quarter despite year-over-year revenue growth, raising questions about whether the steep discount reflects genuine value or deteriorating fundamentals. This filing is notable primarily as a test of whether an insider with a poor historical timing record can successfully identify a bottom in a stock already down substantially from recent highs.

MGM Resorts director Keith A. Meister sold 37,500 shares at $34.27 on 2026-03-09, retaining 5,347,978 shares post-transaction.

Meister sold 37,500 shares (0.7% of his pre-transaction holdings) at $34.27, with MGM currently trading at $35.64, -10.4% from its 52-week high of $39.77. His prior MGM sales (September 2025, June 2025) showed mixed outcomes: the September sell saw a subsequent -11.7% 30-day decline but a +5.0% 90-day return, while the June sales produced +18.2% and +16.7% 30-day gains with +10.1% and +8.7% 90-day returns respectively. None of his 3 prior MGM sells were well-timed at the 90-day mark. MGM's fundamentals show net income of -$285.3M (latest quarter) against revenue of $4.3B, a high P/E of 46.29, and modest annual revenue growth of +1.7%. The modest sale size relative to his 5.35M-share position and the stock's current proximity to year-to-date lows offer limited directional signal.

Director Keith A. Meister purchased 169,521 shares ($13.5M) at GeneDx across 10 transactions on 2026-03-03/05, raising holdings to 3.23M shares (+5.5%).

Director Meister executed 10 separate purchases totaling 169,521 shares for $13,460,089.63 at an average price of $79.40 over two trading days (2026-03-03 to 2026-03-05), significantly expanding a position already representing substantial company ownership. This transaction occurs as the stock trades at $82.00, down 51.0% from its 52-week high of $167.52 and down 13.9% over the past 30 days, yet Meister's prior trades at this ticker show a perfect 5 of 5 win rate at the 90-day mark with returns ranging from +84.0% to +94.6%. The company carries a negative full-year net income of $-7,635,000.00 despite strong revenue growth of 40.0% year-over-year, trading at a P/E of 71.93 on a $2.4B market cap. The scale and deliberate multi-tranche execution of this purchase, combined with Meister's consistent success timing WGS buys in the past, provides a meaningful signal regarding insider conviction during a period of significant stock weakness.

Director Meister Keith A. bought 1,010,064 shares for $6,874,339.00 at Vestis Corp (VSTS) in two transactions on 2025-12-16 and 2025-12-17.

Keith A. Meister, a director of Vestis Corp, executed 2 separate open-market purchases totaling 1,010,064 shares for $6,874,339.00 at a blended average price of $6.81 per share on consecutive trading days. The transactions increased his holdings by 5.4% to 19,813,963 shares post-transaction. At the time of purchase, the stock was -57.7% from its 52-week high of $16.45 and has risen 34.4% over the past 30 days and 67.7% over the past 90 days from the transaction dates. Notably, a cluster pattern is present—2 other insiders also bought within the past 14 days. However, Meister's own prior trading history at VSTS shows 0 of 5 prior buys were well-timed at the 90-day mark, with cumulative 90-day underperformance. The company generated $673.8M in revenue in the latest quarter but remains unprofitable with negative full-year net income and declining year-over-year revenue of -2.5%.

Director Meister sells 242,000 MGM shares at $35.42; retains 5,385,478 shares post-sale

Keith A. Meister sold 242,000 shares (representing a -4.3% reduction in holdings) at $35.42 on 2025-09-11, grossing $8.6M while maintaining a substantial position of 5,385,478 shares. The current price of $35.34 sits -15.8% below the 52-week high of $41.99, and the transaction occurred within the last 30 days at a price above the current level. His cross-ticker track record shows a 60.00% well-timed rate on sells (10 prior sells, avg 90d return +18.5%), but this represents a mixed history of timing accuracy across different stocks. At MGM specifically, he has executed 5 prior trades with only 2 of 5 sells achieving negative 90-day returns (well-timed); the two most recent sales in June 2025 posted positive 90-day returns of +10.1% and +8.7%, suggesting he sold before subsequent gains rather than before declines. The transaction represents an isolated partial reduction in an otherwise large consolidated stake.

Director Meister sells 60,000 MGM shares for $1,925,550.06; stock down 32.2% from 52-week high, mixed timing history

Keith A. Meister (Director) executed two separate sales totaling 60,000 shares for $1,925,550.06 on 2025-06-13 at a blended average price of $32.09, reducing his holdings by 1.1% to 5,627,478 shares. The transaction occurred when MGM stock is -32.2% from its 52-week high ($46.78) and -9.2% over the past 30 days, suggesting a decline in valuation context. Examining his prior activity at MGM specifically: 4 of his 5 prior trades at this ticker were well-timed at the 90-day mark, with a pattern of sales that often preceded further declines. However, his cross-ticker track record shows 8 prior sells with an average 90d return of +20.8% (90d well-timed rate 75.00%), indicating his sells have generally been well-positioned; his most recent MGM sale on 2024-12-13 saw 90d -17.5%, consistent with this pattern. The transaction amount ($1.9M) represents a modest portfolio adjustment for someone holding 5.63M shares, and the timing during a period of stock weakness aligns with his historical precedent of selling at or before price inflection points.

Director Meister Keith A. bought 800,675 shares across 3 transactions (May 23–28) at blended average $5.97, raising holdings to 18.80M shares.

Director Meister Keith A. executed three separate purchases totaling 800,675 shares for $4,777,431.63 between May 23 and May 28, with transaction prices ranging from $5.89 to $6.05. This increased his holdings by 4.4% to 18.80M shares. The current price of $6.04 sits 63.7% below the 52-week high of $16.62, and the stock has declined 31.6% over 30 days and 49.4% over 90 days, indicating substantial recent volatility. Vestis Corp's fundamentals show net income of -$27.8M against quarterly revenue of $665.2M, with flat annual revenue growth at -0.7%, suggesting operational headwinds. While Meister's cross-ticker track record shows 7 prior buys and 8 prior sells with a 75% well-timed rate on the sells, his prior trades at VSTS (2 purchases on May 8 and May 9) have no yet-measurable 30- or 90-day outcomes, limiting the ability to assess whether this buying pattern reflects informed conviction or mechanical accumulation during a significant drawdown.